Shilpa Medicare Limited — PPTs, 13-08-2025: Investor Presentation

Here's a summary of the attached document, tailored to your preferences:

**1. Financial Highlights:**

Q1FY26 revenue up 9% YoY to INR 328 Cr, led by API (+25% YoY) and Biologics. Record EBITDA of INR 98 Cr (+18% YoY), margins 30%. PAT surged 236% to INR 47 Cr. Balance sheet strong: 1.6x Net Debt/EBITDA, 9.1% ROCE.

**2. Strategic Initiatives & Growth Drivers:**

API capacity expansion (UDCA, Nilotinib) to drive FY26 growth. Biologics: Novel Biological Entities target Phase I (FY27), Aflibercept in Phase III. Recombinant Human Albumin starts India/EU Phase III this fiscal. CDMO eyes two NCE commercializations by FY27.

**3. Business Developments:**

Partner launched 2nd US NDA (Bortezomib RTU). Historic approval for NorUDCA (India’s first NAFLD therapy); Q3FY26 revenue expected. New commercial contracts secured. Initial milestone payments received from Orion for Recombinant Human Albumin.

**4. Market Position & Competitive Advantage:**

R&D leadership shown by first global NAFLD approval. "Clone-to-vial" CDMO and integrated small molecule/biologics platforms offer comprehensive, differentiated solutions. Recombinant Human Albumin provides competitive edge via patented, assured supply.

**5. Investor Implications:**

Robust pipeline and operational leverage from underutilized high-margin assets signal positive growth. Expect meaningful margin expansion, enhanced profitability in FY26. Licensing deals converting to long-term supply agreements strengthen future revenue.